Roll-out of the vaccination campaign in Luxembourg

The stockpile of COVID-19 vaccine doses continues to grow steadily. Indeed, with the arrival of the first doses of Moderna vaccine in addition to the doses of Pfizer/BioNTech vaccine already delivered, the order for 300 million additional doses that the European Commission has managed to negotiate with Pfizer and the prospect of the possible marketing authorisation of AstraZeneca's vaccine by the end of the month, the roll-out of the Luxembourg vaccination campaign is progressing at a good pace.

The various components of the vaccination strategy are closely and continuously monitored by the Ministry of Health and the Office of the High Commission for National Protection, through a working group dedicated to the vaccination strategy and its various components.

The supply component is at the centre of the efforts of this working group, which liaises with the European Commission's "COVID vaccines" steering committee and the vaccine manufacturers.

The tables below reflect the amounts in doses to which Luxembourg is theoretically entitled according to the pro rata of 0.14% of the Luxembourg population as provided for in the contracts already concluded by the Commission with the various manufacturers (table 1) as well as the amounts already delivered to the Grand Duchy to date and expected to be delivered by the end of March 2021 (table 2).

It should be noted that the amounts shown in Table 1 are only theoretical. The final amounts will be announced by manufacturers at the time of conditional authorisation by the European Medicines Agency (EMA), on the basis of the delivery and production capacities at the time. ​

The amounts shown in table 2 are subject to adjustment from week to week based on manufacturers' production capacities.

 

Table 1: theoretical doses of vaccine planned for Luxembourg, on the basis of the contracts concluded by the European Commission

Vaccine

Total number of people

Total amount of doses

AstraZeneca

207,524

415,048

Janssen (Johnson&Johnson)

276,156

276,156

Pfizer / BioNtech

337,645

675,290

Curevac

164,700

329,399

Moderna

55,231

110,462

Sanofi-GSK*

210,000

420,000

TOTAL

1,251,256

2,226,355

*Contract not yet concluded by the European Commission

 

Table 2: amount of doses already delivered and forecast up to the end of March 2021 (subject to adjustment from week to week)

Vaccine

Doses 28.12.

20

Doses 11.01.

21

Doses 18.01.

21

Doses 25.01.

21

Doses 01.02.

21

Doses 08.02.

21

Doses 15.02.

21

Doses 22.02.

21

Doses 01.03.

21

Doses 08.03.

21

Doses 15.03.

21

Doses 22.03.

21

Doses 29.03.

21

Total of confirmed doses

Pfizer / BioNtech Comirnaty

9,750

4,875

4,875

3,900

4,875

4,875

4,875

4,875

5,850

5,850

5,850

7,800

9,750

78,000

Moderna

 

1,200

 

1,200

1,200

 

4,800

 

 

 

 

 

 

8,400

TOTAL**

9,750

6,075

4,875

5,100

6,075

4,875

9,675

4,875

5,850

5,850

5,850

7,800

9,750

86,400

** this number corresponds to the number of vaccine doses. The number of people who can be vaccinated with these doses is half of each of these numbers. In total, these number of doses will therefore make it possible to vaccinate 43,200 people.

 

From the week of 18 January, the ECDC will publish a set of data on the roll-out of vaccination campaigns in EU Member States. This publication will provide a comparative overview on the basis of structured data.

 

Press release by the Ministry of State, the Ministry of Health and the High Commission for National Protection

Last update